NEXT, The Danish Association of the Pharmaceutical Industry (Lif) and Invest in Denmark have published a report made by Copenhagen Economics which quantifies the value generated by clinical trials in Denmark.
The main conclusions of the report are: Clinical trials by pharmaceutical companies deliver value to the Danish society. On average, a clinical trial improves GDP by DKK 0.9m and the public budget by DKK 1.2m.
The positive economic effects arise from trials conducted in Denmark through several drivers: More and better healthcare, highly productive jobs and new research in Life Sciences.
The executive summary is available in English here: engelsk resume
The full report is available in Danish.